

Date: October 22, 2024

To
The Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 543064

Scrip Symbol: SUVENPHAR

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Ref: Scheme of amalgamation of Cohance Lifesciences Limited (“Transferor Company”) into and with Suven Pharmaceuticals Limited (“Transferee Company”) under Sections 230 to 232 of the Companies Act, 2013, the Companies (Compromises, Arrangements and Amalgamations) Rules, 2016 and other rules and regulations framed thereunder (“Scheme of Amalgamation”).

Dear Sir/Madam,

This is with reference to, and in furtherance of: (a) our letter dated February 29, 2024, regarding the decision of the Board of Directors of Suven Pharmaceuticals Limited approving the Scheme of Amalgamation of Cohance Lifesciences Limited (“**Transferor Company**”) into and with Suven Pharmaceuticals Limited (“**Transferee Company**”) under Sections 230 to 232 of the Companies Act, 2013 and other applicable rules and/or regulations, subject to receipt of applicable regulatory and other approvals (the “**Scheme of Amalgamation**”); (b) our letter dated July 23, 2024 regarding the subsequent developments in the Scheme of Amalgamation; and (c) our letter dated July 25, 2024, regarding filing of the joint application by the Transferor Company and the Transferee Company for the Scheme of Amalgamation under Sections 230 to 232 of the Companies Act, 2013 and other applicable provisions, before the Hon’ble National Company Law Tribunal, Mumbai Bench (“**NCLT**”).

In the above context, we are pleased to inform that the NCLT, *vide* its order pronounced on October 22, 2024 (as uploaded on the official website of the NCLT on October 22, 2024 (<https://nclt.gov.in/>)) (the “**Order**”) has, amongst other things:

- (i) directed the convening of the meetings of the shareholders of both the Transferor Company and the Transferee Company, for approving the Scheme of Amalgamation, at a date and time as may be decided by the chairperson (appointed by the NCLT under the Order) in consultation with the counsel for the applicant companies, subject to giving 30 days’ notice as per the provisions of the Companies Act, 2013 and the Companies (Compromises, Arrangements and Amalgamations) Rules, 2016;
- (ii) dispensed with the meetings of secured creditors and unsecured creditors of both the Transferor Company and the Transferee Company;
- (iii) directed the Transferor Company and Transferee Company to issue notices to their respective unsecured creditors for seeking their representation, if any, in relation to the Scheme of Amalgamation; and
- (iv) directed the Transferor Company and the Transferee Company to serve notices on the concerned regulatory authorities, as set out in the Order, for seeking their representations, if any, in relation to the Scheme of Amalgamation.

We request you to take this disclosure on your records.

Thanking you.

Yours faithfully,
For **Suven Pharmaceuticals Limited**

Kundan Kumar Jha
Company Secretary, Compliance Officer and Head-Legal

Suven Pharmaceuticals Limited

Registered Office: # 215 Atrium, C Wing, 8th Floor,
819-821, Andheri Kurla Road, Chakala, Andheri East,
Chakala Midc, Mumbai- 400093, Maharashtra, India
Tel: 91 22 61539999

Corporate Office: # 202, A-Wing, Galaxy Towers,
Plot No.1, Hyderabad Knowledge City, TSIIIC,
Raidurg, Hyderabad - 500081 Telangana, India
Tel: 91 40 2354 9414 / 3311

Email: info@suvenpharm.com | Website: www.suvenpharm.com | CIN: L24299MH2018PLC422236